Global Partners Announces Cash Distribution on Series B Preferred Units

Global Partners Announces Cash Distribution on Series B Preferred Units

WALTHAM, Mass.–(BUSINESS WIRE)–
Global Partners LP (NYSE: GLP) (the “Partnership”) today announced that the Board of Directors (the “Board”) of its general partner, Global GP LLC, has declared a quarterly cash distribution of $0.59375 per unit ($2.375 per unit on an annualized basis) on the Partnership’s 9.50% fixed-rate Series B preferred units for the period from May 15, 2025 through August 14, 2025. The distribution will be paid on August 15, 2025 to Series B preferred unitholders of record as of the opening of business on August 1, 2025.

Non-U.S. Withholding Information

Concurrent with this announcement we are providing qualified notice to brokers and nominees that hold Global Partners LP units on behalf of non-U.S. investors under Treasury Regulation Section 1.1446-4(b) and (d) and Treasury Regulation Section 1.1446(f)-4(c)(2)(iii). Brokers and nominees should treat one hundred percent (100%) of Global Partners LP’s distributions to non-U.S. investors as being attributable to income that is effectively connected with a United States trade or business. In addition, brokers and nominees should treat one hundred percent (100%) of the distributions as being in excess of cumulative net income for purposes of determining the amount to withhold. Accordingly, Global Partners LP’s distributions to non-U.S. investors are subject to federal income tax withholding at a rate equal to the highest applicable effective tax rate plus ten percent (10%). Nominees, and not Global Partners LP, are treated as the withholding agents responsible for withholding on the distributions received by them on behalf of non-U.S. investors.

About Global Partners LP

Building on a legacy that began more than 90 years ago, Global Partners has evolved into a Fortune 500 company and industry-leading integrated owner, supplier, and operator of liquid energy terminals, fueling locations, and guest-focused retail experiences. Global operates or maintains dedicated storage at 54 liquid energy terminals—with connectivity to strategic rail, pipeline, and marine assets—spanning from Maine to Florida and into the U.S. Gulf States. Through this extensive network, the company distributes gasoline, distillates, residual oil, and renewable fuels to wholesalers, retailers, and commercial customers. In addition, Global owns, operates and/or supplies approximately 1,700 retail locations across the Northeast states, the Mid-Atlantic, and Texas, providing the fuels people need to keep them on the go at their unique guest-focused convenience destinations. Recognized as one of Fortune’s Most Admired Companies, Global Partners is embracing progress and diversifying to meet the needs of the energy transition.

Global, a master limited partnership, trades on the New York Stock Exchange under the ticker symbol “GLP.” For additional information, visit www.globalp.com.

Forward-looking Statements

Certain statements and information in this press release may constitute “forward-looking statements.” The words “believe,” “expect,” “anticipate,” “plan,” “intend,” “foresee,” “should,” “would,” “could” or other similar expressions are intended to identify forward-looking statements, which are generally not historical in nature, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on Global’s current expectations and beliefs concerning future developments and their potential effect on the Partnership. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Partnership will be those that it anticipates. Forward-looking statements involve significant risks and uncertainties (some of which are beyond the Partnership’s control) including, without limitation, uncertainty around the timing of an economic recovery in the United States which will impact the demand for the products we sell and the services that we provide, and assumptions that could cause actual results to differ materially from the Partnership’s historical experience and present expectations or projections. We believe these assumptions are reasonable given currently available information. Our assumptions and future performance are subject to a wide range of business risks, uncertainties and factors, which are described in our filings with the Securities and Exchange Commission (SEC).

For additional information regarding known material factors that could cause actual results to differ from the Partnership’s projected results, please see Global’s filings with the SEC, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. Global undertakes no obligation to publicly update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise.

Gregory B. Hanson

Chief Financial Officer

Global Partners LP

(781) 894-8800

Sean T. Geary

Chief Legal Officer and Secretary

Global Partners LP

(781) 894-8800

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Retail Energy Convenience Store Oil/Gas

MEDIA:

Logo
Logo

HIMS FRAUD CLASS ACTION: Hims & Hers Health, Inc. Investors may have been Affected by Fraud – Contact BFA Law by August 25 Legal Deadline (NYSE:HIMS)

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action.

Investors have until August 25, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities. The case is pending in the U.S. District Court for the Northern District of California and is captioned Sookdeo v. Hims & Hers Health, Inc., et al., No. 25-cv-05315. A subsequent complaint alleging substantially similar claims was also filed and is captioned Yaghsizian v. Hims & Hers Health, Inc., et al., No. 25-cv-05321.

Why was Hims & Hers Sued for Securities Fraud?

Hims & Hers operates a telehealth platform that provides consumers with access to online consultations with licensed healthcare professionals, prescription medications, and a range of wellness products. On April 29, 2025, Hims & Hers and Novo Nordisk announced a “long-term collaboration” starting with the immediate sale of Novo Nordisk’s popular weight loss drug Wegovy on the Hims & Hers platform. The active ingredient in Wegovy is semaglutide.

As alleged, Hims & Hers touted and misrepresented to investors the nature of its partnership with Novo Nordisk, including asserting that under the terms of the agreement His & Hers could offer both Wegovy and compounded semaglutide to its customers. Hims & Hers also allegedly represented to investors that its sale of compounded semaglutide complied with FDA regulations.

The Stock Declines as the Truth is Revealed

On June 23, 2025, Novo Nordisk announced that it was terminating the partnership, “based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk” and alleged that Hims & Hers “failed to adhere to the law which prohibits mass sales of compounded drugs.” On this news, the price of Hims & Hers stock fell $22.24 per share, or more than 34%, from $64.22 per share on June 20, 2025 to $41.98 per share on June 23, 2025.

Click here for more information:

https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action

.

What Can You Do?

If you invested in Hims & Hers you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USAThe Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action

Attorney advertising. Past results do not guarantee future outcomes.



AAPL FRAUD CLASS ACTION: Apple Inc. Investors may have been Affected by Fraud –Contact BFA Law by August 19 Legal Deadline (NASDAQ:AAPL)

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Apple Inc. (NASDAQ: AAPL) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Apple, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/apple-inc-class-action-lawsuit.

Investors have until August 19, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Apple securities. The case is pending in the U.S. District Court for the Northern District of California and is captioned Tucker v. Apple Inc., et al., No. 5:25-cv-05197.

Why was Apple Sued for Securities Fraud?

Apple is a multinational technology company that engages primarily in the businesses of smart-devices and artificial intelligence (“AI”). Apple’s software includes a digital personal assistant called “Siri,” which was first introduced in October 2011. The complaint alleges that Apple misrepresented Siri’s advanced AI-based features as well as its ability to deliver them within the iPhone 16 product cycle.

In truth, as alleged, Apple lacked a functional prototype of Siri’s purported advanced AI-based features and misrepresented the time it would take to integrate such features into its devices.

The Stock Declines as the Truth is Revealed

On March 7, 2025, Apple announced it was indefinitely delaying several AI-based Siri features, citing development delays and pushing their release to sometime “in the coming year.” On this news, the price of Apple stock declined $11.59 per share, or almost 5%, from $239.07 per share on March 7, 2025, to $227.48 per share on March 10, 2025, the following trading day.

Then, on June 9, 2025, Apple hosted its Worldwide Developer Conference for 2025. Noticeably, Apple failed to announce any new updates regarding advanced Siri features. Analysts and media outlets described the WWDC as “underwhelming” and “disappointing,” with CNN stating that “it’s unlikely that any of the announcements made at Monday’s event will change the perception that Apple is behind its competitors in AI.” On this news, the price of Apple stock declined $2.47 per share, or over 1%, from $203.92 on June 6, 2025, to $201.45 per share on June 9, 2025, the following trading day.

Click here for more information:

https://www.bfalaw.com/cases-investigations/apple-inc-class-action-lawsuit

.

What Can You Do?

If you invested in Apple you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases-investigations/apple-inc-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USAThe Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases-investigations/apple-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.



CNC FRAUD CLASS ACTION: Centene Corporation Investors may have been Affected by Fraud –Contact BFA Law by September 8 Legal Deadline (NYSE:CNC)

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Centene Corporation (NYSE: CNC) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Centene, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/centene-corporation-class-action-lawsuit.

Investors have until September 8, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Centene securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned: Lunstrum v. Centene Corporation, et al., No. 25-cv-05659.

Why was Centene Sued for Securities Fraud?

Centene is a healthcare company that focuses on providing services to consumers enrolled in government-sponsored healthcare programs like Medicaid and Medicare, as well as those that purchase insurance under the Affordable Care Act from the Health Insurance Marketplace.

On December 12, 2024, Centene announced financial guidance for fiscal year 2025 which the company said reflected “[s]tability in earnings power in the face of unprecedented headwinds.” Next, on February 4, 2025, Centene increased its 2025 guidance due to enrollment “overperformance.” Then, on April 25, 2025, Centene again increased 2025 guidance due to continued strong growth in enrollment and retention, while touting the “progress we are making as an organization while navigating a dynamic policy landscape.” In truth, the majority of the market that Centene serves was experiencing lower than expected enrollment growth and increased morbidity rates, or frequency of disease and illness.

The Stock Declines as the Truth is Revealed

On July 1, 2025, Centene abruptly withdrew its previous guidance after reviewing an independent actuarial report from Wakely Consulting Group which showed that overall market growth in 22 of the 29 states Centene serves was lower than expected and that morbidity in those states was significantly higher than expected. On this news, the price of Centene stock fell $22.87 per share, or more than 40%, from $56.65 per share on July 1, 2025 to $33.78 per share on July 2, 2025.

Click here for more information:

https://www.bfalaw.com/cases-investigations/centene-corporation-class-action-lawsuit

.

What Can You Do?

If you invested in Centene you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases-investigations/centene-corporation-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USAThe Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases-investigations/centene-corporation-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.



FTRE FRAUD CLASS ACTION: Fortrea Holdings Inc. Investors may have been Affected by Fraud –Contact BFA Law by August 1 Legal Deadline (NASDAQ:FTRE)

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Fortrea Holdings Inc. (NASDAQ: FTRE) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Fortrea you are encouraged to obtain additional information by visiting

https://www.bfalaw.com/cases-investigations/fortrea-holdings-inc-class-action-lawsuit
.

Investors have until August 1, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Fortrea securities.   The case is pending in the U.S. District Court for the Southern District of New York and is captioned Deslande v. Fortrea Holdings Inc., et al., No. 1:25-cv-04630.

Why was Fortrea Sued for Securities Fraud?

Fortrea is a global contract research organization that provides biopharmaceutical product and medical device development solutions. In June 2023, Fortrea was spun off into a standalone, publicly traded company by Labcorp Holdings Inc. (“Labcorp”). In connection with the spin-off, Fortrea entered into several transition services agreements (the “TSAs”), pursuant to which it agreed to pay Labcorp for certain transitional services over a set period.

As alleged, Fortrea discussed the significant cost savings and margin improvements that would result from exiting the TSAs. In truth, Fortrea overstated the cost savings and margin improvement it would achieve by exiting the TSAs, as well as the amount of revenue it would generate from pre-spin projects.

The Stock Declines as the Truth is Revealed

On September 25, 2024, investment bank Jefferies published a report stating that the cost savings Fortrea would achieve from exiting the TSAs were “[n]ot as [m]aterial as [o]ne [m]ight [t]hink.” On this news, the price of Fortrea stock declined $2.73 per share, or over 12%, from a closing price of $22.21 per share on September 24, 2024, to $19.48 per share on September 25, 2024.

Then, on March 3, 2025, Fortrea announced disappointing Q4 and full year 2024 financial results, revealing that the company’s pre-spin projects “have less revenue and less profitability than expected for 2025” and that “post-spin work is not coming on fast enough to offset the pre-spin contract economics.” On this news, the price of Fortrea stock declined $3.47 per share, or over 25%, from a closing price of $13.85 per share on February 28, 2025, to $10.38 per share on March 3, 2025, the next trading day.

Click here if you suffered losses:

https://www.bfalaw.com/cases-investigations/fortrea-holdings-inc-class-action-lawsuit

.

What Can You Do?

If you invested in Fortrea you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases-investigations/fortrea-holdings-inc-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USAThe Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases-investigations/fortrea-holdings-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.



RDDT FRAUD CLASS ACTION: Reddit, Inc. Investors may have been Affected by Fraud –Contact BFA Law by August 18 Legal Deadline (NYSE:RDDT)

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Reddit, Inc. (NYSE: RDDT) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Reddit, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/reddit-inc-securities-fraud-class-action.

Investors have until August 18, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Reddit securities. The case is pending in the U.S. District Court for the Northern District of California and is captioned Tamraz, Jr. v. Reddit, Inc., at al., No. 25-cv-05144.

Why was Reddit Sued for Securities Fraud?

Reddit owns and operates the eponymous social news aggregation, forum, and social media platform. Reddit receives a significant portion of its user traffic from individuals seeking answers to questions using Google Search. The complaint alleges that Reddit misrepresented and downplayed the impact that Google’s use of Artificial Intelligence (“AI”) technology in Google’s search results had on Reddit’s user growth.

In truth, Google’s use of AI dented Reddit’s user growth by eliminating the need for individuals to visit and click through to Reddit to get answers to their questions. Rather, the answers appeared through Google’s AI search results.

The Stock Declines as the Truth is Revealed

On May 1, 2025, Reddit reported a significant slowdown in daily active user growth. On this news, the price of Reddit stock declined $4.96 per share, or more than 4%, from $118.79 per share on May 1, 2025, to $113.83 per share on May 2, 2025.

Then, on May 21, 2025, Wall Street analyst Baird cut its Reddit stock price target over concerns that Google’s AI capabilities are stifling Reddit’s user growth. On this news, the price of Reddit stock fell $9.79 per share, or over 9%, from $105.64 per share on May 20, 2025, to $95.85 per share on May 21, 2025.

Click here for more information:

https://www.bfalaw.com/cases-investigations/reddit-inc-securities-fraud-class-action

.

What Can You Do?

If you invested in Reddit you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases-investigations/reddit-inc-securities-fraud-class-action

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USAThe Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases-investigations/reddit-inc-securities-fraud-class-action

Attorney advertising. Past results do not guarantee future outcomes.



OLO INVESTIGATION ALERT: The Olo Inc. Board may have Breached its Fiduciary Duties – Current Shareholders are Notified to Contact BFA Law (NYSE:OLO)

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Olo Inc. (NYSE: OLO), its board of directors, its executive officers, and founder and current CEO Noah H. Glass for potential breaches of their fiduciary duties to shareholders in connection with the pending sale of Olo to Thoma Bravo Discover Fund IV, L.P. (“Thoma Bravo”) for $10.25 per share.

If you are a current shareholder of Olo, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/olo-inc-merger-investigation.

Why is Olo being Investigated?

Olo is an open SaaS platform for restaurants that powers restaurant brands’ on-demand digital commerce operations, enabling digital ordering, delivery, engagement, and payments. Olo common stock is divided into Class A and Class B shares. Class A shares are publicly traded, whereas Class B shares are not. Class B shares receive ten votes per share, while Class A shares receive only one vote. As of December 31, 2024, “directors and executive officers and their affiliates collectively beneficially owned, in the aggregate, shares representing approximately 82% of the voting power of our outstanding capital stock.”

On July 3, 2025, Olo announced that it had entered into a definitive agreement to be acquired by Thoma Bravo in an all-cash transaction valuing Olo at approximately $2 billion in equity value. Under the terms of the agreement, Olo shareholders will receive $10.25 per share in cash. The per-share purchase price purportedly represents a premium of 65% over Olo’s unaffected share price of $6.20 as of April 30, 2025.

BFA Law is investigating whether Olo’s board of directors, its executive officers, and/or Glass breached their fiduciary duties to shareholders in connection with the merger.

Click here for more information:

https://www.bfalaw.com/cases-investigations/olo-inc-merger-investigation

.

What Can You Do?

If you are a current holder of Olo you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases-investigations/olo-inc-merger-investigation

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USAThe Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases-investigations/olo-inc-merger-investigation

Attorney advertising. Past results do not guarantee future outcomes.



OGN FRAUD CLASS ACTION: Organon & Co. Investors may have been Affected by Fraud – Contact BFA Law by July 22 Legal Deadline (NYSE:OGN)

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Organon you are encouraged to obtain additional information by visiting

https://www.bfalaw.com/cases-investigations/organon-co-class-action
.

Investors have until July 22, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities.   The case is pending in the U.S. District Court for the District of New Jersey and is captioned: Hauser v. Organon & Co., et al., No. 25-cv-05322.

Why was Organon Sued for Securities Fraud?

Organon is a global healthcare company focused on women’s health that has historically rewarded its shareholders with a healthy dividend. In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company focused on dermatological conditions. As alleged, while the acquisition increased Organon’s debt, the Company assured investors it would maintain its dividend, which Organon asserted was its “#1 capital allocation priority.”

In truth, Organon had shifted its capital allocation priority after the Dermavant acquisition to focus on reducing its debt, ultimately leading the Company to severely cut its dividend.

The Stock Declines as the Truth is Revealed

On May 1, 2025, Organon announced that management reset the Company’s dividend payout from $0.28 per share to $0.02 per share. Organon’s CEO explained that the Company “reset our capital allocation priorities to accelerate progress towards deleveraging” and that “[b]y deleveraging more rapidly, we will continue to strengthen the future prospects of the company.” Organon’s CFO added, “[t]he biggest issues we face . . . relate to managing our leverage and relate to growth. And we need capital to solve both of those issues, and so returning capital to shareholders is right now, less of a priority.”

On this news, the price of Organon stock declined roughly 27%, from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025.

Click here if you suffered losses:

https://www.bfalaw.com/cases-investigations/organon-co-class-action

.

What Can You Do?

If you invested in Organon you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases-investigations/organon-co-class-action

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USAThe Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases-investigations/organon-co-class-action

Attorney advertising. Past results do not guarantee future outcomes.



Shareholder Alert: The Ademi Firm Investigates Whether Veritex Holdings, Inc. Is Obtaining a Fair Price for Its Public Shareholders

Shareholder Alert: The Ademi Firm Investigates Whether Veritex Holdings, Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE–(BUSINESS WIRE)–
The Ademi Firm is investigating Veritex (NASDAQ: VBTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Huntington.

Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.

In the transaction, shareholders of Veritex will receive 1.95 shares for each outstanding share of Veritex. Based on Huntington’s closing price of $17.39 on July 11, 2025, the consideration implies $33.91 per Veritex share.

Veritex insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for Veritex by imposing a significant penalty if Veritex accepts a competing bid. We are investigating the conduct of the Veritex board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Ademi & Fruchter LLP

Guri Ademi

Toll Free: (866) 264-3995

Fax: (414) 482-8001

KEYWORDS: United States North America Wisconsin

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo

Niagen Bioscience Announces the Debut of Tru Niagen®and Niagen IV at Equinox Hotel New York

Niagen Bioscience Announces the Debut of Tru Niagen®and Niagen IV at Equinox Hotel New York

Both Tru Niagen, featured as the newest in-room offering for hotel guests, and Niagen IV, available at NutriDrip’s location at The Spa by Equinox Hotel New York, support cellular energy production and DNA repair for optimal recovery

LOS ANGELES–(BUSINESS WIRE)–Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the inaugural hotel debut of Tru Niagen® as an in-room amenity at the Equinox Hotel New York, and Niagen IV, now available at the hotel’s spa through NutriDrip.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250714863706/en/

Tru Niagen, now available in all Equinox Hotel suites

Tru Niagen, now available in all Equinox Hotel suites

Rob Fried, CEO of Niagen Bioscience, remarked, “Our partnership with Equinox Hotel and NutriDrip underscores our commitment to growing consumer access, driving brand strength, and capturing new market opportunities for our flagship Niagen products.”

Equinox Hotels, a luxury hospitality brand built on the evolution of Equinox, has been thoroughly conceptualized and brought to life to translate a high-performance lifestyle into a seamless guest experience through cutting-edge and science-backed fitness, recovery, and nutrition services. Hotel guests can now experience the transformative cellular health benefits of Tru Niagen, the number one healthy-aging NAD+ supplement in the United States, with bottles available as the newest in-room offering. Additionally, the groundbreaking pharmaceutical-grade product, Niagen IV, is available at The Spa by Equinox Hotel New York through NutriDrip.

Angela Portella, Director of Spa at Equinox Hotel, commented, “At Equinox Hotels, we provide our community with the highest quality, science-backed products and services. Tru Niagen, recognized as the gold-standard NAD+-boosting supplement, and NutriDrip, the best in the IV therapy business, reflect our mission.”

Tru Niagen and Niagen IV are powered by Niagen Bioscience’s clinically proven flagship ingredient, Niagen® (patented nicotinamide riboside or NR), the most efficient, well-researched, and high-quality NAD+ booster available. NAD+ is a vital coenzyme found in every cell of the human body that supports cellular energy production and DNA repair to support recovery.

Asa Kitfield, Managing Partner at Clean Market & NutriDrip, remarked, “We are thrilled to offer Niagen IV at our premium Equinox Hotel New York location. This cutting-edge infusion represents a profound advancement for elevating NAD+ intravenously. It’s a game-changer for muscle health and recovery.”

About Tru Niagen and Niagen IV

Tru Niagen is backed by the highest scientific and quality standards, including a Nobel Prize winner, 35+ human clinical studies, 400+ published scientific studies, and has been accepted by the world’s most rigorous regulatory bodies. All Tru Niagen products are third-party certified, with Tru Niagen Pro 1,000mg and Tru Niagen Stick Packs NSF Certified for Sport, ensuring their safety, quality, and integrity for elite athletes and fitness enthusiasts alike.

Niagen IV represents a significant advancement in intravenous NAD+-boosting therapy. NAD+ IV has gained popularity amongst doctors, fitness experts, celebrities, and athletes because of the substantial benefits, but the experience can be unpleasant. In a head-to-head comparison with NAD+ IV, Niagen IV offered superior tolerability, a 75% shorter infusion time, and resulted in a statistically significant 20% increase in whole blood NAD+ levels three hours post-infusion (MedRxiv).

For additional information on the science supporting Niagen, visit www.niagenbioscience.com. Learn more about Equinox Hotel New York at www.equinox-hotels.com and NutriDrip at www.nutridrip.com.

About Niagen Bioscience:

Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.

The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.

Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There’s a better way to age.

At the heart of its clinically proven product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen powers the Company’s consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States (available at www.truniagen.com), and Niagen Plus, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (www.niagenplus.com). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription.

Niagen Bioscience’s robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com, where copies of press releases, news, and financial information are regularly published.

Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1/1/2024 – 12/31/2024).

About Equinox Hotels

Equinox Hotels is a rapidly expanding, global luxury hospitality brand and management company built off the evolution of Equinox. With a design-forward perspective and 360-approach to luxury lifestyle, our portfolio spans urban, resort, and destination locations globally set in architecturally stunning spaces built for high-performance living. Only Equinox Hotels can seamlessly integrate a hotel experience with an existing community of engaged, loyal members who activate the Clubs daily. Equinox Branded Residences offer lifestyle, status, and the notion of health associated with the Equinox brand and global membership. Equinox Hotels has a robust global pipeline that is defining a new category of luxury.

For more information on Equinox Hotels please visit:

www.equinox-hotels.com

About NutriDrip

As a leader in functional wellness, NutriDrip provides IV Nutrient Therapy for therapeutic and rejuvenating benefits with a full menu of signature Wellness and Recovery IV Drips. Traditional oral supplementation is hard for your body to absorb and results are slow, while IV Nutrient Therapy provides 100% bioavailability for fast-acting results. NutriDrip’s signature IV Drips, which are administered by nurse practitioners and registered nurses, utilize fluids, electrolytes, vitamins and minerals to help you feel & function better. Knowing that we all have different health and nutritional needs, NutriDrip takes a personalized approach to wellness with a best-in-class medical team that will help select and customize the right IV Drip protocol for you.

Forward Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to infringement or non-infringement of intellectual property rights. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects,” “anticipates,” “intends,” “estimates,” “plans,” “potential,” “possible,” “probable,” “believes,” “seeks,” “may,” “will,” “should,” “could” or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

Niagen Bioscience Media Contact:

Kendall Knysch, Senior Director of Media Relations & Partnerships

310.405.5227

[email protected]

Niagen Bioscience Investor Relations Contact:

ICR, LLC

Reed Anderson

(646) 277-1260

Stephanie Carrington

(646) 277-1282

[email protected]

Equinox Hotels Media Contact:

Caroline McKay

[email protected]

KEYWORDS: United States North America California New York

INDUSTRY KEYWORDS: Research Pharmaceutical Lodging Destinations Travel Fitness & Nutrition Clinical Trials Science Biotechnology Alternative Medicine Vitamins/Supplements Health

MEDIA:

Photo
Photo
Tru Niagen, now available in all Equinox Hotel suites
Photo
Photo
NutriDrip provides Niagen IV at The Spa by Equinox Hotel
Logo
Logo